• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary pharmacology & therapeutics >The role of budesonide/formoterol for maintenance and relief in the management of asthma.
【24h】

The role of budesonide/formoterol for maintenance and relief in the management of asthma.

机译：布地奈德/福莫特罗在维持和缓解哮喘管理中的作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of asthma management is to gain and maintain asthma control and reduce the risk of future exacerbations. However, despite the availability of effective therapies and national and international guidelines for their use, many patients remain inadequately controlled and continue to endure and accept a reduced quality of life. This review discusses current challenges in asthma management facing primary care physicians and provides insight into new treatment strategies developed to improve asthma control. A web-based literature review was undertaken with a focus on studies and reviews discussing asthma control and management with traditional therapies and new therapies, including a novel treatment approach using budesonide/formoterol maintenance and reliever therapy. One of the most common problems in long-term asthma control is poor adherence to inhaled corticosteroid (ICS) maintenance therapy, resulting in under-treatment of inflammation. Many patients tend to over-rely on short-acting beta(2)-agonist medication for quick relief of symptoms at the expense of ICS therapy, thus lowering anti-inflammatory protection and increasing the propensity for the development of severe and potentially life-threatening exacerbations. New simplified treatment strategies have been investigated with the aim of overcoming many of these primary care challenges, ultimately improving asthma control and reducing the future risk of exacerbations.
机译：哮喘控制的目的是获得和维持哮喘控制并降低未来加重的风险。但是，尽管有有效的治疗方法以及国家和国际使用指南，但许多患者仍未得到足够的控制，继续忍受并接受了生活质量下降。这篇综述讨论了初级保健医生在哮喘管理方面当前面临的挑战，并提供了对改善哮喘控制的新治疗策略的见识。进行了基于网络的文献综述，重点是讨论和讨论传统疗法和新疗法对哮喘的控制和管理，包括采用布地奈德/福莫特罗维持和缓解疗法的新型治疗方法。长期控制哮喘的最常见问题之一是对吸入性糖皮质激素（ICS）维持治疗的依从性差，导致炎症的治疗不足。许多患者倾向于过度使用短效β（2）受体激动剂来快速缓解症状，却以ICS治疗为代价，从而降低了抗炎保护并增加了严重且可能危及生命的发展的可能性。恶化。为了克服许多这些初级保健挑战，最终改善了哮喘控制并降低了未来加重病的风险，已经研究了新的简化治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号